+226.1%
PM vs MRNA
+786.4%
-560.2%
-31.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.3% | -2.2% | +0.9% | -1.2% |
| 7D | -7.5% | -12.7% | +5.2% | -7.4% |
| 30D | -6.8% | -20.7% | +13.9% | -6.7% |
| 3M | -3.1% | +46.3% | -49.3% | -3.3% |
| 6M | -0.8% | +305.2% | -306.0% | -1.8% |
| YTD | +17.8% | +561.2% | -543.5% | +16.1% |
| 1Y | +22.5% | +772.1% | -749.6% | +20.6% |
| 3Y | +125.4% | +147.0% | -21.6% | +124.3% |
| 5Y | +156.3% | -26.1% | +182.4% | +155.8% |
| All | +226.1% | +786.4% | -560.2% | +206.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling